These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6147316)

  • 1. The genetic control of drug oxidation in the liver.
    Dayer P; Balant L; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):421-5. PubMed ID: 6147316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].
    Dayer P; Courvoisier F; Kupfer A; Balant-Gorgia A; Balant L; Fabre J
    Schweiz Med Wochenschr; 1983 Feb; 113(8):295-7. PubMed ID: 6133350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consequences of renal insufficiency on the hepatic clearance of some drugs.
    Balant LP; Dayer P; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
    Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
    Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methods for studying the hepatic metabolism of drugs in man].
    Geneve J; Bergmann JF; Caulin C; Segrestaa JM
    Therapie; 1990; 45(2):91-7. PubMed ID: 2191470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol].
    Tschopp JM; Gorgia A; Balant L; Revillard C; Francis RJ; Fabre FJ
    Schweiz Med Wochenschr; 1978 May; 108(20):756-64. PubMed ID: 26114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in human drug metabolism and its implications.
    Breimer DD
    Int J Clin Pharmacol Res; 1983; 3(6):399-413. PubMed ID: 6381339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic control of bufuralol metabolism in man.
    Dayer P; Balant L; Courvoisier F; Kupfer A; Kubli A; Gorgia A; Fabre J
    Eur J Drug Metab Pharmacokinet; 1982; 7(1):73-7. PubMed ID: 6121708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
    Eichelbaum M
    Internist (Berl); 1983 Mar; 24(3):117-27. PubMed ID: 6135670
    [No Abstract]   [Full Text] [Related]  

  • 13. [Stability and/or variability of the expression of genetic polymorphism of hydroxylation and acetylation in patients with various pathologies and under various treatments].
    Bechtel P; Joanne C; Bechtel Y; Grandmottet M; Jounet JM
    Ann Biol Clin (Paris); 1986; 44(4):361-7. PubMed ID: 3538951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
    Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
    Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic polymorphism of the hepatic metabolism of drugs].
    Larrey D; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1985; 9(6-7):522-31. PubMed ID: 3926587
    [No Abstract]   [Full Text] [Related]  

  • 16. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.
    Dayer P; Balant L; Küpfer A; Courvoisier F; Fabre J
    Eur J Clin Pharmacol; 1983; 24(6):797-9. PubMed ID: 6136413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic metabolism of beta-adrenoceptor antagonists.
    Silas JH; Lennard MS; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):11S-19S. PubMed ID: 6146335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidation phenotype and the metabolism and action of beta-blockers.
    Lennard MS
    Klin Wochenschr; 1985 Apr; 63(7):285-92. PubMed ID: 2860267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.